Pfizer-Allergan $160 bn deal: Interesting facts and outcomes

Zee Media Bureau

In the biggest ever deal in healthcare sector, Pfizer Inc, the maker of Viagra and Lipitor, is all set to buy Botox-maker Allergan thereby creating the world's biggest drugmaker.

Let's take a look at some of the interesting facts from the record USD 160 billion deal.

• At $160 billion, the deal is the biggest in the world of healthcare sector and will help create the world's biggest drugmaker.
• The deal is bigger than Pfizer's 2000 purchase of Warner- Lambert Co for USD 116 billion.
• Post the deal, Pfizer head Ian Read will be CEO of the combined company, while Allergan CEO Brent Saunders will be chief operating officer.
• The merged company's board is expected to have 15 directors, consisting of all of Pfizer's 11 current directors and four current directors of Allergan.
• The deal will also allow Pfizer to shift its legal base to Ireland for tax purposes.
• The combined company is expected to generate annual operating cash flow in excess of USD 25 billion.
• Allergan shareholders will receive 11.3 shares in the combined company for each share held with the shares of the botox maker valued at $363.63 each.
• Pfizer stockholders will have the option of receiving one share of the combined company for each of their Pfizer shares or receive cash, provided the aggregate amount of cash to be paid is not less than $6 billion or more than $12 billion.
• The businesses of Pfizer and Allergan will be combined under Allergan Plc and will be renamed Pfizer.

With Agency Inputs